Waganuga

Wugen is a clinical-stage biotechnology company focused on developing the next generation of off-the-shelf cell therapies for cancer. The company utilizes a proprietary platform to create "memory" Natural Killer (NK) cells and CAR-T cells that are designed to be more potent and persistent than traditional cell therapies. Their lead programs target T-cell malignancies and acute myeloid leukemia, addressing significant unmet needs in hematological cancers. By leveraging healthy donor cells, Wugen aims to provide readily available, scalable treatments that do not require the complex logistics of patient-specific manufacturing.